The identification of KRASG12C inhibitors has reignited interest in focusing on RAS proteins. This perform describes the invention on the KRASG12D-certain inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively concentrating on this oncogenic variant. These findings, Dr. L